Mediplantex National Pharmaceutical Joint Stock Company

HNX:MED Stock Report

Market Cap: ₫297.8b

Mediplantex National Pharmaceutical Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Thanh Mai

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenureless than a year

Recent management updates

Recent updates

CEO

Thanh Mai

less than a year
Tenure

Mr. Thanh Nhat Mai is General Director & Member of Board of General Directors of Mediplantex National Pharmaceutical Joint Stock Company from January 2, 2025.

Leadership Team

NamePositionTenureCompensationOwnership
Lam Le
Vice Director & Member of Board of General Directorsless than a year₫480.81mno data
An Tran
Vice Directorless than a year₫329.33mno data
Tuan Tran
Chief Accountantno data₫571.52mno data
Thanh Mai
General Director & Member of Board of General Directorsless than a yearno datano data
0.5yrs
Average Tenure

Experienced Management: MED's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
An Tran
Vice Directorless than a year₫329.33mno data
Dung Tran
Chairman of the Boardless than a year₫1.13b8.06%
₫ 24.0b
Hanh Thi Ha
Member of the Board of Supervisionless than a yearno datano data
Dinh Tran
Member of the Boardless than a year₫620.01mno data
Thuy Do
Member of the Board of Supervisionless than a yearno datano data
Minh Thai
Member of the Boardless than a year₫35.00mno data
Thuy Nguyen
Member of the Boardless than a year₫35.00mno data
Tuan Ho
Head of the Board of Supervisionless than a yearno datano data
0.9yrs
Average Tenure

Experienced Board: MED's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 04:29
End of Day Share Price 2025/05/23 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mediplantex National Pharmaceutical Joint Stock Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.